Starten Sie Ihre Suche...


Durch die Nutzung unserer Webseite erklären Sie sich damit einverstanden, dass wir Cookies verwenden. Weitere Informationen
Publikationen
Ergebnisse pro Seite:  10

Imre, Gergely; Kraehling, Verena; Eichler, Madeleine et al.

The sphingosine kinase 1 activator, K6PC-5, attenuates Ebola virus infection

ISCIENCE. Bd. 24. H. 4. 2021


Sadanandam, Anguraj; Bopp, Tobias; Dixit, Santosh et al.

A blood transcriptome-based analysis of disease progression, immune regulation, and symptoms in coronavirus-infected patients

CELL DEATH DISCOVERY. Bd. 6. H. 1. 2020


Yurugi, Hajime; Zhuang, Yinyin; Siddiqui, Farid et al.

A subset of flavaglines inhibits KRAS nanoclustering and activation

JOURNAL OF CELL SCIENCE. Bd. 133. H. 12. 2020


Lauer, Alina; Wolf, Philipp; Mehler, Dorothea et al.

Biofabrication of SDF-1 Functionalized 3D-Printed Cell-Free Scaffolds for Bone Tissue Regeneration

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. Bd. 21. H. 6. 2020


Roth, Klaus Edgar; Betz, Simon; Schmidtmann, Irene et al.

Biological responses to individualized small titanium implants for the treatment of focal full-thickness knee cartilage defects in a sheep model

KNEE. Bd. 27. H. 3. 2020 S. 1078-1092


Wiechmann, Svenja; Maisonneuve, Pierre; Grebbin, Britta M. et al.

Conformation-specific inhibitors of activated Ras GTPases reveal limited Ras dependency of patient-derived cancer organoids

JOURNAL OF BIOLOGICAL CHEMISTRY. Bd. 295. H. 14. 2020 S. 4526-4540


Klein, Anja; Baranowski, Andreas; Ritz, Ulrike et al.

Effect of bone sialoprotein coating on progression of bone formation in a femoral defect model in rats

EUROPEAN JOURNAL OF TRAUMA AND EMERGENCY SURGERY. Bd. 46. H. 2. 2020 S. 277-286


Bogucka, Katarzyna; Pompaiah, Malvika; Marini, Federico et al.

ERK3/MAPK6 controls IL-8 production and chemotaxis

ELIFE. Bd. 9. 2020


Bogucka, Katarzyna; Marini, Federico; Rosigkeit, Sebastian et al.

ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis

CANCER GENE THERAPY. 2020


Bogucka, Katarzyna; Marini, Federico; Rosigkeit, Sebastian et al.

ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis (October, 10.1038/s41417-020-00245-w, 2020)

CANCER GENE THERAPY. 2020